secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2022-09-23T23:59:59+00:00
Accession:  0000784199-22-000171
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion stops PROACT Xa trial; apixaban fails non-inferiority vs warfarin for On-X aortic valves
--------------------------------------------------------------------------------

- DSMB recommended stopping PROACT Xa due to lack of evidence supporting non-inferiority of apixaban to warfarin.
- Blood clots causing stroke occurred more frequently in patients receiving apixaban; trial continuation unlikely to achieve primary endpoint.
- Physicians notified to switch apixaban-arm patients back to warfarin.
- Successful trial would have significantly increased addressable market beginning in 2025; that opportunity is now lost.
- Company reaffirms 2022 double-digit top-line growth and redirects ~$10M annual trial funding to other development and EBITDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419922000171/0000784199-22-000171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419922000171/aort-20220923.htm
  HTML page:      https://secwatch.observer/filing/0000784199-22-000171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer